Partnership talks gain momentum for novel target pipelines, including GENA-104ADC, GENA-120, and GENC-116
[by Kang, In Hyo] Genome & 카지노 바카라, a novel drug development 카지노 바카라, announced on January 8 that it will participate in the 44th Annual JP Morgan Healthcare Conference Virtual (hereinafter referred to as the JP Morgan Healthcare Conference), to be held in San Francisco from January 12 to 15 (local time), with the objective of expanding its global partnership network.
Established in 1983, the JP Morgan Healthcare Conference has evolved into the world's largest healthcare investment forum, convening 카지노 바카라 pharmaceutical and biotechnology companies alongside healthcare-focused investors. The conference serves as a central platform for the presentation of research and development (R&D) achievements and discussion of investment attraction and strategic partnerships.
Following the technology transfer agreement with Debiopharm in 2024 for a novel antibody target applicable to antibody-drug conjugates (ADCs) and a subsequent technology transfer agreement with Ellypes Pharma Limited in 2025 for a novel immuno-oncology therapeutic, Genome & Company is now pursuing additional out-licensing opportunities for ‘GENA-104ADC’ (development code), ‘GENA-120,’ and ‘GENC-116.’ As R&D activities for these key novel-target programs continue to progress smoothly, the company plans to leverage its participation in the JP Morgan Healthcare Conference to expand discussions with a broader range of potential commercialization partners and to further explore consultation opportunities through business meetings.
"With the latest research outcomes obtained since our recent participation at BIO USA, we intend to actively promote the competitiveness of our novel target pipeline currently under development. By rapidly formulating concrete collaboration frameworks with prospective global partners, we aim to demonstrate that our R&D strategy of 'achieving at least one technology transfer per year' is being executed steadily and effectively," said Hong Yoo-seok, CEO of Genome & Company.
Conversely, Genome & Company has already inked two technology transfer agreements in its novel target pipeline, underscoring the competitiveness of its R&D capabilities in the global market. In particular, 'EP0089’ (development code), licensed to Ellipses Pharma in 2025, is expected to enter global Phase 1 patient enrollment. The company anticipates that this advancement will represent a meaningful milestone, demonstrating the successful and timely transition of its new drug candidate to the commercialization stage.